OMNI Medical Services continues the expansion of medical cannabis offerings with advanced precision medical technologies and services in strategic partnerships with Endocanna Health Inc. and the RYAH Group. Endocanna Health's EndoDNA test kits analyze essential biomolecules in the human endocannabinoid system to formulate and identify the ratios of CBD and cannabis the body metabolizes most effectively. It also explores optimal method of consumption and dosing based on metabolic function and drug-to-drug interactions.

RYAH's patented web-based inhaler and dermal patches assist doctors and patients in personalizing plant-based treatments. Combined with OMNI Medical Services' experience with medical cannabis doctors and patients, the triad of offerings provides advanced insights for patients, doctors, and technology providers in determining what strains their body metabolizes best. OMNI is preparing a major study in collaboration with Endocanna Health to determine the best strain of plant-based medicines for patients by analyzing their endocannabinoid system.

The research study is in conjunction with the RYAH Group and will incorporate RYAH's patented web-based inhaler and dermal patches to assist doctors and patients with predicted superior outcomes.